Short Term Traders-Listed Stocks

[jwalk]

Yes, they have set the board for the Crohn's advisory panel in such a way that approval might not happen. Personally, I think this is an over reaction, and bought all I could afford at the 105 EMA (18.20). I'm subject to the rule about selling before funds clear, so I will likely hold for a few days. I certainly would not advocate this for everyone.

As you can see, I'm down even more right now.

http://www.pharmalot.com/2007/07/fda-tysabri-panel-violates-new-conflict-rule/

excerpt:
You read it here first. Of the 16 voting members of the two committees meeting Tuesday - the Gastrointestinal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee - three members reported conflicts of interest, and received waivers. One, in particular, appears to violate the FDA’s own, newly proposed rules for panel members